financetom
Business
financetom
/
Business
/
Honeywell spinoff Solstice to continue M&A playbook post separation
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Honeywell spinoff Solstice to continue M&A playbook post separation
Oct 8, 2025 11:14 AM

Oct 8 (Reuters) - Solstice Advanced Materials will

continue to look for merger and acquisition opportunities as a

standalone company, its CEO David Sewell said on Wednesday,

seeking to emulate parent Honeywell's ( HON ) deal-making

strategy.

The producer of specialty chemicals, which is set to start

trading independently on the Nasdaq from October 30, was spun

off from Honeywell ( HON ) as part of its separation into three

independent companies.

"We'll look for bolt-on M&A opportunities in the markets and

technologies that are aligned and adjacent to where we're at

today," Sewell told Reuters in an interview ahead of the

company's inaugural investor day.

Honeywell ( HON ) CEO Vimal Kapur has made a string of acquisitions

since he took over in 2023, while also shedding non-aligned

assets to simplify the business.

Solstice is expected to follow that playbook as its

independent structure will help increase focus on capital

allocation and strengthen its balance sheet.

Solstice's refrigerants & applied solutions business logged

sales of $2.7 billion in 2024, while the electronic & specialty

materials unit, which makes electronic materials for

semiconductors, did sales of $1 billion.

Sewell expects the vast amounts of capital flowing into data

centers for artificial intelligence to drive growth at the

business.

"We think that really positions us well to grow along with

the market," Sewell said.

He shrugged off any potential impact from the Trump

administration's tariffs as a result of local manufacturing,

adding higher costs on raw materials is "very manageable."

"It's really not of substance in the impact of our

business."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved